{"id":"W3042095160","doi":"10.1136/jitc-2020-000891","title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center","keywords":"Nivolumab; Medicine; Sunitinib; Ipilimumab; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007920773,0.001549559,0.002862857,0.0004472898,0.0008058517,0.001514412,0.001059998,0.001943732,0.003575804],"category_scores_gemma":[0.004507714,0.0005788888,0.004515724,0.0005394498,0.001208057,0.00167831,0.0006867353,0.003869429,0.0007101443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001571453,"about_ca_system_score_gemma":0.001937369,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007487682,"about_ca_topic_score_gemma":0.001747178,"domain_scores_codex":[0.9970711,0.001883101,0.0001982237,0.000387404,0.0001956097,0.0002643907],"domain_scores_gemma":[0.9953907,0.0009848466,0.001710528,0.0004547073,0.0003017235,0.001157546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9717891,0.007541189,0.004788685,0.0002691463,0.002046179,0.00003202231,0.00006773455,0.0004852355,0.001091598,0.00004515102,0.0006943506,0.01114958],"study_design_scores_gemma":[0.8052247,0.170584,0.01856909,0.00005324503,0.002112951,0.00008494368,0.00004742943,0.001329765,0.0008039385,0.0003122567,0.0008401073,0.00003769583],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915285,0.003120333,0.0003493703,0.0005246765,0.0002056549,0.002297345,0.0009241567,0.00006133151,0.000988566],"genre_scores_gemma":[0.9933364,0.0008134764,0.0006085351,0.0005760083,0.0002694159,0.002660897,0.001080639,0.00001237314,0.0006423135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007920773,"threshold_uncertainty_score":0.04188955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04926157250532811,"score_gpt":0.3799343260798284,"score_spread":0.3306727535745003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}